drugset / Trial / NCT00102830

Study Evaluating AMG 386 in Adult Patients With Advanced Solid Tumors

NCT00102830

Phase 1 Completed Amgen
Treatment

Summary

The purpose of this study is to test the safety, tolerability and pharmacokinetic (PK) profile of AMG 386 after intravenous administration in adult subjects with advanced solid tumors.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Trebananib Peptide Intravenous

Indications